Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2
Annals of the rheumatic diseases. 2021 Mar 1;80(3):312-20.
View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
Annals of the rheumatic diseases. 2021 Mar 1;80(3):312-20.
J Eur Acad Dermatol Venereol 2020;34:2809–2820.
RMD Open 2020;6:e001374 doi:10.1136/rmdopen-2020-001374
Annals of the Rheumatic Diseases 05 August 2020 2020 Nov;79(11):1400-1413. doi: 10.1136/annrheumdis-2019-216761. Epub 2020 Aug 5.
Annals of the Rheumatic Diseases 2020;79:778-786
Rheumatol Ther 2020 doi.org/10.1007/s40744-020-00209-4
Drug Saf. 2020;43:379-392
JAMA Dermatol 2020;156:649–58. doi 10.1001/jamadermatol.2020.0723
Blauvelt et al. shows superior and sustained efficacy for risankizumab in maintaining skin clearance over time versus placebo upon withdrawal, alongside a favourable safety profile in chronic plaque psoriasis through a phase 3, randomised, double-blind, placebo-controlled study, assessing PASI 90 and sPGA score of 0/1 at Week 16.
Clin Rheumatol. 2020
Please click the links below to go to the CSF review of each paper